<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR22">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sun</surname>
    <given-names>W</given-names>
   </name>
   <name>
    <surname>Triche</surname>
    <given-names>T</given-names>
    <suffix>Jr</suffix>
   </name>
   <name>
    <surname>Malvar</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Gaynon</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Sposto</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Bittencourt</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Place</surname>
    <given-names>AE</given-names>
   </name>
   <name>
    <surname>Messinger</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Fraser</surname>
    <given-names>C</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium</article-title>
  <source>Blood</source>
  <year>2018</year>
  <volume>131</volume>
  <issue>10</issue>
  <fpage>1145</fpage>
  <lpage>1148</lpage>
  <pub-id pub-id-type="doi">10.1182/blood-2017-09-803809</pub-id>
  <?supplied-pmid 29339403?>
  <pub-id pub-id-type="pmid">29339403</pub-id>
 </element-citation>
</ref>
